Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma

Asthma Clinical Trial

Official title:

A Phase 2a, Double-Blinded, Multi-Center, Escalating Dose Group, Placebo Controlled, Cross-Over Study to Evaluate the Safety, Efficacy and Tolerability of Subcutaneously Administered PL-3994 for the Treatment of Patients With Mild to Moderate Asthma

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01304628
• Other study ID #: PL-3994-501
• Status: Withdrawn
• Phase: Phase 2
• First received: February 22, 2011
• Last updated: December 15, 2014

Study information

• Verified date: December 2014
• Source: Palatin Technologies
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate if single subcutaneous (SC) doses of PL-3994, administered to patients with asthma can achieve a clinically meaningful increase in pulmonary function (Forced Expiratory Volume in one second: FEV1) while maintaining an acceptable safety profile. The study will characterize the bronchodilator effect, dose and safety of PL-3994 in a population of moderately severe, stable asthmatics following overnight withdrawal of beta-2 agonists.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Subject has provided written informed consent

• The subject is male or female >18 to 65 years of age

• Patient has a clinical history of asthma as defined by the National Asthma Education and Prevention Program.

• Documented bronchodilator response to albuterol as defined by the American Thoracic Society (> 200 mL and > 12% increase in FEV1 after bronchodilator inhalation)

• FEV1 post-bronchodilator of between 55% and 80% predicted.

• Currently taking 200-1000 mcg (fluticasone equivalent) of inhaled corticosteroids

• All inclusion criteria met within the past 12 months.

• If the subject or subject's partner is of child-bearing potential, a medically acceptable form of contraception will be used for three months prior to the screening visit (females only), for the duration of the study and for one month following the last dose of the study drug. Medically acceptable contraceptives include: (1) surgical sterilization, (2) FDA-approved female hormonal contraceptives, (3) an intrauterine device (IUD), (4) condoms with spermicide, or (5) diaphragm with spermicide.

If the subject had a vasectomy greater than 6 months prior to the screen visit, this will also be acceptable.

Exclusion Criteria:

• Current diagnosis, as per subject or investigator or screening assessment, of:

• unstable or uncontrolled disease in any organ system (including cardiovascular) on present therapy

• psychiatric disease requiring daily medication, including controlled or uncontrolled schizophrenia or any other uncontrolled psychiatric condition

• significant neurological disease

• current or history of any cancer (except non-melanomatous skin cancer) diagnosed less than 5 years prior to screening

• acute or chronic disease requiring frequent changes in medications or changes in dosages of chronic therapy

• history of alcohol abuse within the past 5 years

• positive result for the alcohol and/or drug tests at screening or check-in

• positive for HIV, or Hep B&C at screening

• blood donation within 30 days of screening or plasma donation within 7 days of screening

• weight > 100 kg or < 50 kg

• clinically significant electrocardiogram (ECG) at screening

• any clinically significant (per the investigator) lab abnormalities

• any fever or other clinically significant physical exam abnormalities

• History of COPD or any other lung disease

• Greater than 10 packs per year smoking history and any cigarette smoking within the past 12 months

• Patients unable to withhold bronchodilator treatment for 12 hours prior to dosing

• Patients with hypoxia at screen or Check -in Visit 2, Day 1 or Visit 3, Day 7 (oxygen saturation measured by pulse oximetry [SpO2] < 90%)

• Tachycardia (heart rate > 100 beats/min) at screening

• Currently being treated for Hypertension or taking any other medications that affect blood pressure significantly.

• Currently taking any medications that inhibit PDE activity or which affect the cyclic guanisine mono-phosphate (cGMP) pathway (e.g. theophylline). These medications will be prohibited during the study and for at least 5 half- lives prior to Check-in Visit 2, Day 1 or Visit 3, Day 7 so that cGMP measurements will not be affected.

• Hypotension (systolic blood pressure < 110 mmHg) at Screening or Check-in Visit 2, Day 1 or Visit 3, Day 7

• Chronic kidney disease defined as estimated glomerular filtration rate (eGFR) <50 mL/m2.

• Diagnosis of heart failure or history of hospitalization for congestive heart failure.

• History of coronary artery disease defined as prior myocardial infarction, prior revascularization procedure, or >50% coronary artery obstruction by angiography.

• Prior history of stroke or transient ischemic attack.

• Female patients of childbearing potential who are nursing or have a positive pregnancy test at Screening or Check -in Visit 2, Day 1 or Visit 3, Day 7

• Any major disability or disease with expected survival less than 6 months

• Administration of any investigational drug or implantation of investigational device, or participation in another trial, within 30 days of screening.

• Inability to perform acceptable, quality serial spirometry

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• PL-3994
subcutaneous PL-3994, single dose, 4 escalating dose groups

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Palatin Technologies

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Forced Expiratory Volume in one second (FEV1)	Serial spirometry measures, including FEV1, assessed at specified time periods over 12 hours post dose.	Throughout 12 hours post dosing	No
Secondary	Change in Forced Vital Capacity (FVC)	Serial spirometry measures, including FVC, assessed at specified time periods over 12 hours post dose.	Throughout 12 hours post dosing	No